These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10763709)

  • 1. Vaccination in the neonatal period and early infancy.
    Siegrist CA
    Int Rev Immunol; 2000; 19(2-3):195-219. PubMed ID: 10763709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice.
    Siegrist CA; Barrios C; Martinez X; Brandt C; Berney M; Córdova M; Kovarik J; Lambert PH
    Eur J Immunol; 1998 Dec; 28(12):4138-48. PubMed ID: 9862350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for vaccines during pregnancy and in the newborn period.
    Fischer GW; Ottolini MG; Mond JJ
    Clin Perinatol; 1997 Mar; 24(1):231-49. PubMed ID: 9099512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life.
    Gans H; DeHovitz R; Forghani B; Beeler J; Maldonado Y; Arvin AM
    Vaccine; 2003 Jul; 21(24):3398-405. PubMed ID: 12850348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine responses in newborns.
    Saso A; Kampmann B
    Semin Immunopathol; 2017 Nov; 39(6):627-642. PubMed ID: 29124321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators.
    Kovarik J; Siegrist CA
    Immunol Cell Biol; 1998 Jun; 76(3):222-36. PubMed ID: 9682966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell-mediated immune responses in human newborns: ready to learn?
    Marchant A; Goldman M
    Clin Exp Immunol; 2005 Jul; 141(1):10-8. PubMed ID: 15958064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal immunization: where do we stand?
    Wood N; Siegrist CA
    Curr Opin Infect Dis; 2011 Jun; 24(3):190-5. PubMed ID: 21415741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal Immunization: Rationale, Current State, and Future Prospects.
    Whittaker E; Goldblatt D; McIntyre P; Levy O
    Front Immunol; 2018; 9():532. PubMed ID: 29670610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenges of vaccine responses in early life: selected examples.
    Siegrist CA
    J Comp Pathol; 2007 Jul; 137 Suppl 1():S4-9. PubMed ID: 17559867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal interleukin-12 capacity is associated with variations in allergen-specific immune responses in the neonatal and postnatal periods.
    Prescott SL; Taylor A; King B; Dunstan J; Upham JW; Thornton CA; Holt PG
    Clin Exp Allergy; 2003 May; 33(5):566-72. PubMed ID: 12752583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.
    Feunou PF; Kammoun H; Debrie AS; Locht C
    Vaccine; 2014 Jul; 32(34):4281-8. PubMed ID: 24950361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal Vaccination: Challenges and Intervention Strategies.
    Morris MC; Surendran N
    Neonatology; 2016; 109(3):161-9. PubMed ID: 26757146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model.
    Thirugnanam S; Pandiaraja P; Ramaswamy K; Murugan V; Gnanasekar M; Nandakumar K; Reddy MV; Kaliraj P
    Exp Parasitol; 2007 Aug; 116(4):483-91. PubMed ID: 17442307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.
    Vono M; Eberhardt CS; Mohr E; Auderset F; Christensen D; Schmolke M; Coler R; Meinke A; Andersen P; Lambert PH; Mastelic-Gavillet B; Siegrist CA
    Front Immunol; 2018; 9():381. PubMed ID: 29541075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
    Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
    Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.